No­var­tis bets PRV on its next big mul­ti­ple scle­ro­sis drug — eyes US, EU ap­provals in '19

One of No­var­tis’ top late-stage can­di­dates for mul­ti­ple scle­ro­sis is now un­der re­view on both sides of the At­lantic.

Hav­ing stoked en­thu­si­asm for sipon­i­mod through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER